Plasma derived von Willebrand factor preparations: Collagen binding and ristocetin cofactor activities

Thrombosis and Haemostasis

Volumn 78, Issue 2, 1997, Pages 930-933

  Chang, Ping ^a   Aronson, D L ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; HEMATE; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACCURACY; ARTICLE; BLOOD COMPONENT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; PLASMA; PRIORITY JOURNAL; ULTRACENTRIFUGATION; VON WILLEBRAND DISEASE;

EID: 0030841895     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657654     Document Type: Article

References (28)

1. Mannucci PM. Biochemical characteristic of therapeutic plasma concentrates used in the treatment of von Willebrand's disease. Haemostasis 1994; 24: 285-8.
2. Berntorp E. Plasma product treatment in various type of von Willebrand's disease. Haemost 1994; 24: 289-97.
3. Fricke W, Yu M. Characterization of von Willebrand factor in factor VIII concentrates. Am J Haematol 1989; 31: 41-5.
4. Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet activating factor. J Lab Clin Med 1975; 85: 318.
5. Howard MA, Firkin BG. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Hemorrh 1972; 26: 362-9.
6. Brown JE, Bosak JO. An ELISA test for binding of von Willebrand factor antigen to collagen. Thromb Res 1986; 43: 303-11.
7. Favaloro EJ, Gripso L, Exner T, Koutts J. Development of a simple collagen-based ELISA aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II von Willebrand's disease. Blood Coagulation and Fibrinolysis 1991; 2: 285-91.
8. Lawrie AS, Harrison P, Armstrong AL, Wilbourn BR, Dalton RG, Savidge GF. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates. Brit J Haemal 1989; 73: 100-4.
9. Chang P, Aronson DL. A microtiter plate reader assay for factor VIII. Thromb Res 1992; 66: 599-602.
10. Puri S, Gresham C, Kao KJ. A simple quantitative assay for ristocetin cofactor activity using microtiter plates and ELISA plate reader. Thrombosis Research 1994; 74: 285-91.
11. Scharrer IM, Vigh T, Aygoren-Pursun E. Experience with Haemate P in von Willebrand's disease in adults. Haemost 1994; 24: 298-303.
12. Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand's disease. Thromb Haemost 1994; 71: 173-9.
13. Retzios A, Arkel Y, Bhattacharya P, Bray G, Gringeri A, Lipton R, Mannucci PM, Tradati F. Efficacy and safety of Alpha 8R in the treatment of von Willebrand's disease. Thromb Haemost 1993; 69: 2304 (abstract).
14. Pasi KJ, Williams MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Brit J Haemat 1990; 75: 228-33.
15. Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation of a von Willebrand factor concentrate with low factor VIII activity. Brit J Haemat 1992; 80: 214-21.
16. Aronson DL, Chang P. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations. Vox Sang 1995; 69: 8-13.
17. Foster PA. A perspective on the use of factor VIII concentrates and cryoprecipitate prophylacticaly in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP. Thromb Haemost 1995; 74: 1370-8.
18. Boda Z, Pflieger G, Harsfalvi J, Rak K. Treatment of the severe bleeding episode in type III von Willebrand's disease by simultaneous administration of cryoprecipitate and platelet concentrate. Blood Coag and Fibrinolysis 1991; 2: 775-7.
19. Bloom AL, Peake IR, Furlong RA, Davies BL. High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand's disease and inhibitor. Thromb Res 1979; 16: 847-52.
20. Green D, Potter EV. Failure of AHF concentrate to control bleeding in VWD. Am J Med 1976; 10: 357-60.
21. Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand's disease: Dissociation of bleeding time factor and ristocetin-cofactor activities. JAMA 1976; 236: 2770-2.
22. Weinstein M, Deykin D. Comparison of factor-VIII related von Willebrand proteins prepared from human cryoprecipitate and factor VIII concentrate. Blood 1979; 53: 1095-105.
23. Martin SE, Marder VJ, Francis CW, Barlow GH. Structural studies on the functional heterogeneity of von Willebrand protein polymers. Blood 1981, 57: 313-23.
24. Sixma JJ, Sakariassen KS, Beeser-Visser. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 1984; 63: 128-38.
25. Fischer BE, Kramer G, Mitterer A, Grillberger L, Reiter M, Mundt W, Dorner F, Eibl J. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996; 84: 55-66.
26. Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994, 83: 3018-27.
27. Hathaway WE, Mahasandana C, Clarke S, Humbert JR. Paradoxical bleeding in intensively transfused hemophiliacs: alteration of platelet function. Transfusion 1973; 13: 6-12.
28. Jakab T, Pflugshaupt R, Furlan M, Beck EA. Variable degradation of factor-VIII related protein in lyophilised concentrates of antihemophilic factor (AHF). Vox Sang 1978; 35: 36-40.